Sound Income Strategies’s CRISPR Therapeutics CRSP Stock Holding History

Sound Income Strategies’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-127	Closed	-$6.2K	–	879
2026 Q1	$6.2K	Sell	127 -25	-16%	-$1.32K	﹤0.01%	1735
2025 Q4	$8.13K	Buy	152 +25	+20%	+$1.5K	﹤0.01%	1588
2025 Q3	$9.52K	Sell	127 -20	-14%	-$1.15K	﹤0.01%	1020
2025 Q2	$7.15K	Hold	147	–	–	﹤0.01%	1016
2025 Q1	$5K	Buy	147 +20	+16%	+$848	﹤0.01%	1060
2024 Q4	$5K	Hold	127	–	–	﹤0.01%	981
2024 Q3	$5.97K	Hold	127	–	–	﹤0.01%	916
2024 Q2	$6.86K	Hold	127	–	–	﹤0.01%	860
2024 Q1	$8.66K	Sell	127 -5	-4%	-$358	﹤0.01%	796
2023 Q4	$8.26K	Buy	132 +5	+4%	+$276	﹤0.01%	781
2023 Q3	$5.76K	Hold	127	–	–	﹤0.01%	721
2023 Q2	$7.13K	Hold	127	–	–	﹤0.01%	657
2023 Q1	$5.74K	Hold	127	–	–	﹤0.01%	679
2022 Q4	$5.16K	Hold	127	–	–	﹤0.01%	644
2022 Q3	$8K	Hold	127	–	–	﹤0.01%	499
2022 Q2	$8K	Hold	127	–	–	﹤0.01%	501
2022 Q1	$8K	Sell	127 -331	-72%	-$20.8K	﹤0.01%	510
2021 Q4	$35K	Sell	458 -16	-3%	-$1.4K	﹤0.01%	281
2021 Q3	$53K	Hold	474	–	–	0.01%	220
2021 Q2	$77K	Buy	474 +347	+273%	+$42.2K	0.01%	194
2021 Q1	$15.5K	Buy	+127	New	+$19.2K	﹤0.01%	398

Other funds holding CRSP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Sound Income Strategies's CRSP Position: Q2 2026 in Review

Sound Income Strategies sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 127 shares — an estimated $6.2K sold.

Sound Income Strategies first reported a position in CRSP in Q1 2021 and held it in 21 quarters. The position peaked at $77K in Q2 2021. 350 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Sound Income Strategies reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
Sound Income Strategies sold 127 CRISPR Therapeutics shares in Q2 2026, an estimated $6.2K.
Sound Income Strategies first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 21 quarters.
Sound Income Strategies's CRISPR Therapeutics position peaked at $77K in Q2 2021.
350 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.